Avalyn Pharma director proposes $6.25M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
144
Rhea-AI Filing Summary
Avalyn Pharma Inc. (AVLN) director and officer Lyn Baranowski gave notice of a proposed sale of 210,000 common shares, with an aggregate market value of $6,249,600 and an approximate sale date of November 17, 2026.
Key Figures
Common shares proposed for sale: 210,000 shares
Aggregate market value: $6,249,600
Common shares outstanding: 44,521,494 shares
3 metrics
Common shares proposed for sale
210,000 shares
Approximate sale date: November 17, 2026
Aggregate market value
$6,249,600
Value listed for the proposed sale
Common shares outstanding
44,521,494 shares
Number listed in the notice
Key Terms
stock options, Rule 10b5-1
2 terms
stock options financial
"received upon exercise of stock options over the next three months"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Rule 10b5-1 regulatory
"relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.